Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of trastuzumab rezetecan plus carboplatin with or without bevacizumab versus investigator's choice chemotherapy in platinum-sensitive recurrent ovarian cancer
ChiCTR2600133356Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab rezetecan in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-Free Survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600133356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133356.